- Home
- KLRS vs MDCX Comparison
KLRS vs MDCX Comparison
Compare KLRS & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | MDCX |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 53.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | MDCX |
|---|---|---|
| Price | $8.40 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $20.67 | ★ $23.50 |
| AVG Volume (30 Days) | 170.2K | ★ 305.0K |
| Earning Date | 02-24-2026 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $1.45 |
| 52 Week High | $12.90 | $8.94 |
Technical Indicators
Market Signals| Indicator | KLRS | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 51.92 | 38.85 |
| Support Level | $7.92 | $1.45 |
| Resistance Level | $9.09 | $1.70 |
| Average True Range (ATR) | 0.94 | 0.13 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 10.47 | 36.57 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.